ClinicalTrials.gg
Not yet recruitingNCT06908772Updated Apr 3, 2025

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

A Phase 2/3 interventional study of Glumetinib Tablets and Osimertinib Mesylate Tablets in Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression, sponsored by Shanghai JMT-Bio Inc.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.

Read the detailed description

In the Phase II stage, eligible subjects who have passed screening will be randomly assigned in a 1:1:1 ratio into the Group 1, Group 2, and Group 3 to receive study treatment:

In the Phase III stage, eligible subjects who have passed screening will be randomly assigned in a 1:1 ratio into the test group and the control group to receive the study treatments, and the RP3D obtained from Phase II will be used as the dose of glumetinib for the test group.

Randomization stratification factors include: c-MET status (≥2+, ≥75% and 3+, \<50% vs 3+, ≥50% or FISH positive), and EGFR-sensitive mutation type (19Del vs L858R).

In both the Phase II and Phase III stages, each treatment cycle is every 3 weeks, with continuous treatment until progressive disease (PD) confirmed by the investigator, intolerable toxicity, withdrawal of informed consent by the subject, loss to follow-up, death, or other criteria for terminating treatment as specified in the protocol, whichever occurs first.

02

Conditions studied

  • Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Browse trials for

03

In context

Lead sponsor

Shanghai JMT-Bio Inc. is the lead sponsor of 42 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Able to understand and voluntarily sign the written form (ICF); 2. Male or female subjects aged 18 to 75 years (inclusive). 3. Patients with NSCLC who have unresectable locally advanced or disease; 4. At least one , as defined by 1.1 criteria; 5. performance status of 0 or 1; 6. Expected survival ≥ 3 months; 7. Adequate function of major organs and bone marrow; 8. Women or man of must use highly effective .

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with an EGFR inhibitor or MET inhibitor;
  2. Patients with to meninges; with spinal cord compression; symptomatic and unstable ;
  3. Patients who have taken strong inducers or inhibitors of within 2 weeks prior to the first dose of the study drug, or who cannot discontinue the use of strong CYP3A4 inducers and inhibitors during the study;
  4. Patients with a history of diseases, a history of immunodeficiency, including positive for , or other acquired or congenital immunodeficiency diseases, or a history of organ transplant;
  5. Presence of active infection (e.g., subjects are receiving anti-infection therapy);
  6. Severe or uncontrolled cardiovascular disorder requiring treatment;
  7. nausea, vomiting, chronic gastrointestinal disease, inability to swallow drugs orally;
  8. Women who are pregnant or breastfeeding;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Glumetinib(200 mg) + Osimertinib

    Group 1: Glumetinib 200 mg oral QD + Osimertinib 80 mg oral QD.

    Drug: Glumetinib Tablets · Drug: Osimertinib Mesylate Tablets

  • Experimental
    Glumetinib(300mg) + Osimertinib

    Group 2: Glumetinib 300 mg oral QD + Osimertinib 80 mg oral QD;

    Drug: Glumetinib Tablets · Drug: Osimertinib Mesylate Tablets

  • Experimental
    Osimertinib

    Group 3: Osimertinib 80 mg oral QD.

    Drug: Osimertinib Mesylate Tablets · Drug: Glumetinib Tablets Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2:ORR as assessed by IRC

    Time frame: Up to approximately 30 months after the first participant is enrolled

Secondary outcomes

  1. Phase 2:ORR as assessed by investigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  2. phase 2:PFS as assessed by IRC and investigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  3. Phase 3:PFS as assessed by invetigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  4. Phase 3:ORR as assessed by IRC and investigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  5. phase 2/3:OS

    Time frame: Up to approximately 30 months after the first participant is enrolled

  6. phase 2/3:DCR as assessed by IRC and investigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  7. phase 2/3:DoR as assessed by IRC and investigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  8. phase 2/3:TTR as assessed by IRC and investigator

    Time frame: Up to approximately 30 months after the first participant is enrolled

  9. phase 2/3:Frequency and severity of AEs (NCI CTCAE 5.0)

    Time frame: Up to approximately 30 months after the first participant is enrolled

  10. phase 2/3:PK parameters: The plasma concentration of glumetinib

    Time frame: Up to approximately 30 months after the first participant is enrolled

  11. phase 2/3:Biomarkers: c-MET expression and amplification levels, tumor-related gene mutations

    Time frame: Up to approximately 30 months after the first participant is enrolled

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2028, 44 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 3, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 31, 2030
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06908772
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Apr 3, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glumetinib

Start the discussion